THE FACT ABOUT NEW ADVANCEMENTS IN BRD4 INHIBITION THERAPY ABBV-744 THAT NO ONE IS SUGGESTING

In Section A, contributors will receive distinctive doses and schedules of oral ABBV-744 pill to identify Secure dosing program. Extra members will likely be enrolled in the discovered monotherapy dosign regimen. In Phase B, members will obtain oral ruxolitinib and ABBV-744 is going to be presented as "insert-on" therapy. In Phase C, contributors w